Study supports additional COVID-19 vaccine doses for immunocompromised
In a study of over 89,000 adults hospitalized with COVID-19 symptoms, prior vaccination with two doses of the Pfizer or Moderna vaccine was 77% effective in preventing COVID-19 in immunocompromised patients compared with 90% effective in immunocompetent patients, the Centers for Disease Control and Prevention reported today. The authors recommend three doses and a booster for immunocompromised individuals receiving mRNA COVID-19 vaccines, consistent with CDC recommendations.
Related News Articles
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…